Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

The initial report of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m(2)) improved overall survival in adults <60 years old with acute myel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Luskin, Marlise R., Lee, Ju-Whei, Fernandez, Hugo F., Abdel-Wahab, Omar, Bennett, John M., Ketterling, Rhett P., Lazarus, Hillard M., Levine, Ross L., Litzow, Mark R., Paietta, Elisabeth M., Patel, Jay P., Racevskis, Janis, Rowe, Jacob M., Tallman, Martin S., Sun, Zhuoxin, Luger, Selina M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2016
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4807422/
https://ncbi.nlm.nih.gov/pubmed/26755712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-07-657403
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados